JPI InvestFranΓ§ais
JPI AI Analyst AI assistant Β· JPI Invest
Answers based on the tool's data Β· not financial advice Β· full analysis (free)
All stocks β€Ί Health Care β€Ί COO

Are analysts right about Cooper Companies (The) (COO)?

Health Care Β· price $70.96 Β· median target $85.00 (+20%)
In short β€” Over the past 12 months, 0% of analyst price targets on Cooper Companies (The) turned out profitable, for an average return of -10% (across 12 timestamped calls). The current consensus is "Buy" with a median price target of $85.00 (+20% vs the current $70.96, from 11 analysts).

πŸ“ˆ See the interactive version (live chart) β†’

πŸ”— Related pages on Cooper Companies (The) β€” Financials & fundamentals  Β·  If I had invested
Current price
$70.96
Median target (12 mo)
$85.00 +20%
Analyst accuracy (1 yr)
0%
Avg return / call (1 yr)
-10%
πŸ’° Performance & Β« if I invested Β» πŸ“Š Interactive analysis

Historical analyst accuracy

For Cooper Companies (The), we replayed every analyst price target of the past 12 months and measured the real outcome: 0% were profitable, average return -10% (12 calls). At 3 months: -3% average return (21% profitable). The higher the %, the more often analysts were right on this stock.

Most reliable analysts on this stock (past track record)

Their past track record on this stock (targets replayed against real prices) β€” not a forecast of what will happen.

Not enough scored calls for a reliable ranking.

Valuation

Is Cooper Companies (The) overvalued, and is it a good time to buy Cooper Companies (The) right now? If you're wondering, here's a recap to make up your own mind: Cooper Companies (The)'s valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.

The P/E (price Γ· earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects β€” but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.

MetricCooper Companies (The)Sector median (Health Care)
P/E61.729.4
Forward P/E14.217.1
Net margin6%12%

πŸ‘‰ Cooper Companies (The) trades above its sector median (61.7 vs 29.4) β€” the market expects higher growth; watch out for disappointment.

πŸ“– P/E, PEG, margin…: see the glossary

Frequently asked questions

Is Cooper Companies (The) a buy right now?

The analyst consensus on Cooper Companies (The) (COO) is "Buy" (21 bullish, 2 bearish calls over 12 months). This is not advice: historically, 0% of their targets on this stock turned out profitable over 1 year.

What is Cooper Companies (The)'s price target?

The median 12-month price target is $85.00 (+20% vs $70.96), ranging from $66.00 to $103 (11 analysts).

Are analysts accurate on Cooper Companies (The)?

Over 1 year, 0% of analyst targets on Cooper Companies (The) were profitable, for an average return of -10% (across 12 timestamped calls). This is JPI Invest's accuracy metric.

What is the Cooper Companies (The) stock forecast?

Analysts target a median of $85.00 within 12 months, i.e. +20% vs the current price. The most bullish targets $103, the most cautious $66.00.

What is the Cooper Companies (The) stock forecast for 2026 or long term (2030)?

Note: analyst targets are 12-month (median $85.00, +20%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (0%), and the stock's past trajectory.

Is Cooper Companies (The) overvalued?

Its P/E is 61.7, forward P/E 14.2. A forward P/E lower than the current P/E means earnings are expected to grow.

πŸ“Š See the full interactive analysis of Cooper Companies (The) β†’

What is JPI Invest?

JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β€” on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.

Explore JPI Invest for free β†’ How it works: the method β†’

⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.